Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132028 · ClinicalTrials.gov registry record · Phase 2
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
A Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT00132028: Completed Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, sponsored by National Cancer Institute (NCI).
NCT00132028 is a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants, roughly in line with the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132028, a Phase 2 study of Recurrent Adult Hodgkin Lymphoma and Adult Lymphocyte Depletion Hodgkin Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules fro
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG vorinostat
Study Locations (1)
Texas
- Southwest Oncology Group (SWOG) Research Base - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00132028 record still lists
NCT00132028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, roughly in line with the 29-participant average among 4 other Recurrent Adult Hodgkin Lymphoma trials with a reported enrollment target.
The record links to 8 conditions, with Recurrent Adult Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00132028 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00132028 about?
NCT00132028 is a clinical study titled "Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma". This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT00132028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2005-09. Estimated completion is 2009-05.
What conditions does trial NCT00132028 study?
This clinical trial studies the following conditions: Recurrent Adult Hodgkin Lymphoma, Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma.
What interventions are being tested in trial NCT00132028?
The interventions under investigation include: laboratory biomarker analysis (OTHER), vorinostat (DRUG).
Who is sponsoring clinical trial NCT00132028?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00132028 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
COMPLETED · Phase 2
-
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia